| NCT05660395 | A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) | RECRUITING | PHASE1 | 2023-08-28 | 2027-04-05 | 2026-12 |
| NCT05389462 | A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors | TERMINATED | PHASE1 | 2022-07-13 | 2025-04-17 | 2025-04-17 |
| NCT05144009 | A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) | TERMINATED | PHASE2 | 2022-06-21 | 2024-01-22 | 2024-01-22 |
| NCT04970901 | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | RECRUITING | PHASE1 | 2022-06-17 | 2027-10-29 | 2026-10-30 |
| NCT04974996 | A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8) | WITHDRAWN | PHASE1 | 2022-02-01 | 2027-05-05 | 2024-03-11 |
| NCT04699461 | Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma | TERMINATED | PHASE2 | 2021-11-04 | 2022-11-25 | 2022-11-25 |
| NCT04972981 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors | COMPLETED | PHASE1 | 2021-09-09 | 2024-09-13 | 2024-09-13 |
| NCT04384484 | Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-09-16 | 2028-06-30 | 2025-06-23 |
| NCT04052997 | Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma | COMPLETED | PHASE2 | 2019-09-13 | 2023-01-19 | 2023-01-19 |
| NCT03685344 | Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma | TERMINATED | PHASE1 | 2019-02-04 | 2020-10-27 | 2020-10-27 |
| NCT03700294 | Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors | TERMINATED | PHASE1 | 2018-12-21 | 2019-12-11 | 2019-12-11 |
| NCT03684694 | Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma | TERMINATED | PHASE1, PHASE2 | 2018-12-01 | 2022-11-08 | 2022-11-08 |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | TERMINATED | PHASE1 | 2018-11-09 | 2022-12-14 | 2022-12-14 |
| NCT03589469 | Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | COMPLETED | PHASE2 | 2018-08-01 | 2022-08-09 | 2020-05-24 |
| NCT03125200 | Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression | TERMINATED | PHASE1 | 2017-05-18 | 2018-04-05 | 2018-04-05 |
| NCT02669017 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) | COMPLETED | PHASE1 | 2016-03 | 2019-02-21 | 2019-02-21 |
| NCT02669264 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL) | TERMINATED | PHASE1 | 2016-03 | 2018-07-03 | 2018-07-03 |
| NCT02588092 | Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL) | TERMINATED | PHASE1 | 2016-02-01 | 2018-08-29 | 2018-08-29 |
| NCT02432235 | Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma | COMPLETED | PHASE1 | 2015-10-05 | 2019-10-24 | 2019-10-24 |